AMRI was issued a GMP certificate from the Medicines and Healthcare Regulatory Agency (MHRA) for its manufacturing facility in Holywell, Wales, UK. The MHRA inspection in October 2011, with a formal closeout in January 2012, follows a FDA audit of the facility in June 2011, in which no formal observations were issued. As a result of the successful inspections, AMRI can produce registered intermediates and active ingredients for use in humans and can expand the range of projects it can conduct at...